2-[5-(1,2-Dithiolan-3-yl)pentanoylamino]acetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[5-(1,2-Dithiolan-3-yl)pentanoylamino]acetamide
• 英文别名: N-(2-amino-2-oxo-ethyl)-5-(dithiolan-3-yl)pentanamide；N-(2-amino-2-oxoethyl)-5-(dithiolan-3-yl)pentanamide
• 化学式: C₁₀H₁₈N₂O₂S₂
• 分子量: 262.397
• InChiKey: CYZPTCVRYMKIMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  甘氨酰胺 、 Thioctic acid 在 sodium chloride 、 三乙胺 、 N,N'-羰基二咪唑 作用下， 以 N-甲基乙酰胺 、 水 为溶剂， 生成 2-[5-(1,2-Dithiolan-3-yl)pentanoylamino]acetamide
  参考文献：
  名称：

  Dithiolan derivatives, their preparation and their therapeutic effect

  摘要：

  式（I）的化合物：其中m和n中的一个表示0，另一个表示0、1或2；k表示0或1至12；R.sup.1是氢、芳基、杂环、烷基、羟基或--OR.sup.7，其中R.sup.7是烷基、烯基或芳基烷基；A是--CON(R.sup.2)SO.sub.2--，其中R.sup.2是氢、烷基或芳基烷基；B是单键；以及其药学上可接受的盐。这些化合物具有增强谷胱甘肽还原酶活性的能力，因此可用于治疗和预防包括白内障在内的各种疾病。

  公开号：

  US06013663A1

文献信息

• Dithiolan derivatives, their preparation and their therapeutic effect
  申请人：Sankyo Company, Limited

  公开号：US06013663A1

  公开（公告）日：2000-01-11

  A compound of formula (I): ##STR1## wherein one of m and n represents 0, and the other represents 0, 1 or 2; k represents 0 or 1 to 12; R.sup.1 is hydrogen, an aryl, a heterocyclic, an alkyl, a hydroxy or --OR.sup.7, wherein R.sup.7 is an alkyl, an alkenyl or an aralkyl; A is --CON(R.sup.2)SO.sub.2--, wherein R.sup.2 is hydrogen, an alkyl or an aralkyl; B is a single bond; and pharmaceutically acceptable salts thereof. The compounds have the ability to enhance the activity of glutathione reductase and can therefore be used for the treatment and prevention of a variety of diseases including cataracts.

  式（I）的化合物：其中m和n中的一个表示0，另一个表示0、1或2；k表示0或1至12；R.sup.1是氢、芳基、杂环、烷基、羟基或--OR.sup.7，其中R.sup.7是烷基、烯基或芳基烷基；A是--CON(R.sup.2)SO.sub.2--，其中R.sup.2是氢、烷基或芳基烷基；B是单键；以及其药学上可接受的盐。这些化合物具有增强谷胱甘肽还原酶活性的能力，因此可用于治疗和预防包括白内障在内的各种疾病。
• [EN] BIS-FATTY ACID CONJUGATES AND THEIR USES<br/>[FR] CONJUGUÉS DE BIS-ACIDES GRAS ET LEURS UTILISATIONS
  申请人：CATABASIS PHARMACEUTICALS INC

  公开号：WO2012115695A1

  公开（公告）日：2012-08-30

  The invention relates to bis-fatty acid conjugates; compositions comprising an effective amount of a bis-fatty acid conjugate; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a bis-fatty acid conjugate.

  该发明涉及双脂肪酸共轭物；包含有效量双脂肪酸共轭物的组合物；以及治疗或预防癌症、代谢性疾病或神经退行性疾病的方法，包括给予有效量双脂肪酸共轭物的管理。
• BIS-FATTY ACID CONJUGATES AND THEIR USES
  申请人：Milne Jill C.

  公开号：US20130190327A1

  公开（公告）日：2013-07-25

  The invention relates to bis-fatty acid conjugates; compositions comprising an effective amount of a bis-fatty acid conjugate; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a bis-fatty acid conjugate.

  本发明涉及双脂肪酸共轭物；包含有效量的双脂肪酸共轭物的组合物；以及治疗或预防癌症、代谢性疾病或神经退行性疾病的方法，包括给予有效量的双脂肪酸共轭物。
• N-lipoic-amino acid or peptide, derivatives and their uses
  申请人：NEOSTRATA COMPANY, INC.

  公开号：US11155531B2

  公开（公告）日：2021-10-26

  Novel compounds of N-Lipoic-amino acid, N-Lipoic-peptides and their derivatives are described. Also described are compositions and method of compositions containing the derivatives of the amino acids or peptides, and their uses including treating and preventing dermatological or cosmetic conditions or other disorders of the cutaneous system. Compositions and methods of using the compositions for skin lightening and cosmetics are also disclosed.

  描述了 N-硫辛酸-氨基酸、N-硫辛酸-肽及其衍生物的新型化合物。还描述了含有这些氨基酸或肽衍生物的组合物和组合物的使用方法，以及它们的用途，包括治疗和预防皮肤病或美容病症或皮肤系统的其他疾病。此外，还公开了用于皮肤美白和化妆品的组合物和使用方法。
• USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES
  申请人：Jirousek Michael R.

  公开号：US20140315786A1

  公开（公告）日：2014-10-23

  The present invention relates to targeting an intracellular enzyme for release of covalently linked bioactives which results in a synergistic effect between the bioactives. The present invention relates to the use of bioactives that are directly connected covalently or through a covalent molecular linker which have increased therapeutic activity when released as the free bioactives by intracellular enzymes as compared to when the bioactives are administered individually (i.e. not covalently linked). Further, methods are described of administering to patients in need thereof, bioactives as linked bioactives having increased therapeutic activity. Accordingly, this invention also relates to methods of treating patients for certain diseases.